IMMUNOME, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.94 USD | +1.56% |
|
+5.06% | +39.63% |
| 31/05 | Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target | MT |
| 21/05 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
| Sales 2024 * | 10.04M 838M | Sales 2025 * | 844K 70.4M | Capitalization | 896M 74.73B |
|---|---|---|---|---|---|
| Net income 2024 * | -193M -16.1B | Net income 2025 * | -170M -14.18B | EV / Sales 2024 * | 89.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1,062 x |
| P/E ratio 2024 * |
-4.2
x | P/E ratio 2025 * |
-5.5
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.92% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.56% | ||
| 1 week | +5.06% | ||
| 1 month | -0.20% | ||
| 3 months | -41.30% | ||
| 6 months | +91.54% | ||
| Current year | +39.63% |
1 week
14.21
15.81
1 month
13.5216.79
Current year
10.3830.96
1 year
4.5030.96
3 years
2.0930.96
5 years
2.0963.78
10 years
2.0963.78
| Managers | Title | Age | Since |
|---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 02/23/02 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 02/23/02 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 19/23/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 02/01 |
| Director/Board Member | 70 | 07/11 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 02/23/02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 14.94 | +1.56% | 1,588,124 |
| 30/24/30 | 14.71 | +0.62% | 769,695 |
| 29/24/29 | 14.62 | -.--% | 660,828 |
| 28/24/28 | 14.62 | +2.81% | 712,436 |
Delayed Quote Nasdaq, May 01, 2024 at 01:30 am IST
More quotes
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Calendar
15/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.94
USD
Average target price
32.5
USD
Spread / Average Target
+117.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.63% | 896M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- IMNM Stock
